share_log

Needham Maintains Buy on NextCure, Lowers Price Target to $4

Needham Maintains Buy on NextCure, Lowers Price Target to $4

Needham 维持对NextCure的买入,将目标价下调至4美元
Benzinga ·  2023/12/14 11:30

Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $6 to $4.

Needham分析师吉尔·布鲁姆维持NextCure(纳斯达克股票代码:NXTC)的买入,并将目标股价从6美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发